Mutated IDH1 gene linked to the progression of gliomas (News-Medical-Net)

Agios Pharmaceuticals today announced that its scientists have established, for the first time, that the mutated IDH1 gene has a novel enzyme activity consistent with a cancer-causing gene, or oncogene.
(read here…)

Related items

• OncoGenex Pharmaceuticals to pay Isis Pharmaceuticals $10M for license of OGX-011 to Teva Pharmaceutical Industries (News-Medical-Net)
• World’s first Cs-131 implant for colorectal cancer performed at Weill Cornell Medical Center (News-Medical-Net)
• ‘Smart’ nanocapsule delivery system created for use in protein therapy (Science Daily)
• Rexahn, TheraTarget form nano science research collaboration (PharmaBiz)
• Bayer’s NEXAVAR approved in over 70 countries for the treatment of liver cancer (News-Medical-Net)

Tags: Agios, cancer, enzyme activity, Gene, nano, nanotech, nanotechnology, novel enzyme, oncogene, Pharmaceuticals, Technology, time, today, today announced that

This entry was posted on Tuesday, November 24th, 2009 at 1:54 pm and is filed under Technology.